Free Trial
→ Buy NVDA Now? (From Chaikin Analytics) (Ad)

ChromaDex Q4 2022 Earnings Report

ChromaDex logo
$5.42 -0.28 (-4.91%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

ChromaDex EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.03
Beat/Miss
Beat by +$0.01
One Year Ago EPS
-$0.08

ChromaDex Revenue Results

Actual Revenue
$21.00 million
Expected Revenue
$21.08 million
Beat/Miss
Missed by -$80.00 thousand
YoY Revenue Growth
N/A

ChromaDex Announcement Details

Quarter
Q4 2022
Date
3/8/2023
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Slide Deck

Full Screen Slide Deck
Powered by Quartr

ChromaDex Earnings Headlines

Should Weakness in ChromaDex Corporation's (NASDAQ:CDXC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
February 15, 2025 | finance.yahoo.com
Should Weakness in ChromaDex Corporation's (NASDAQ:CDXC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
February 15, 2025 | finance.yahoo.com
Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
February 22, 2025 | Colonial Metals (Ad)
US Growth Companies With High Insider Ownership January 2025
January 24, 2025 | finance.yahoo.com
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 6, 2025 | businesswire.com
Even though ChromaDex (NASDAQ:CDXC) has lost US$73m market cap in last 7 days, shareholders are still up 389% over 1 year
December 10, 2024 | finance.yahoo.com
See More ChromaDex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ChromaDex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ChromaDex and other key companies, straight to your email.

About ChromaDex

ChromaDex (NASDAQ:CDXC) operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

View ChromaDex Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles